drugset

drugset / Trial / NCT00491998

PK, PD and Safety of Multiple Doses of V1512 Tablets in PD Patients Compared to Standard Levodopa/Carbidopa Oral Tablets

NCT00491998 ↗

Phase 1/2 Completed 27 enrolled Vernalis (R&D) Ltd Cita NeuroPharmaceuticals · collab Syneos Health · collab

RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of the study is to determine if the pharmacokinetic profile of V1512 is similar or better than existing medications for the treatment of Parkinson's Disease

Timeline

Start: 2006-11
Primary completion: 2007-11
Completion: 2007-11

Publications

Stocchi F, Vacca L, Grassini P, Pawsey S, Whale H, Marconi S, Torti M. L-Dopa Pharmacokinetic Profile with Effervescent Melevodopa/Carbidopa versus Standard-Release Levodopa/Carbidopa Tablets in Parkinson's Disease: A Randomised Study. Parkinsons Dis. 2015;2015:369465. doi: 10.1155/2015/369465. Epub 2015 Jun 10.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Entacapone	Small molecule	200 mg	—
Subject	Levodopa	Small molecule	25 mg	—
Subject	Levodopa	Small molecule	100 mg	—

Indications